Business

Biodesix Announces One-for-Twenty Reverse Stock Split

LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix” or the “Company”), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.001, which will become effective at 12:01 a.m. Eastern Time on Monday, September 15, 2025. The Company’s common stock will continue to trade under Biodesix’s existing trading symbol, BDSX, on the Nasdaq Global Market (“Nas

articleBiodesix, Inc.September 11, 20255/company/biodesix-inc/news/biodesix-announces-one-twenty-reverse-120000050
Biodesix Announces One-for-Twenty Reverse Stock Split

About this update from Biodesix, Inc.

[{"type":"image","alt":"Biodesix, Inc.","displaySize":"","headline":null,"caption":"Biodesix, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":110,"url":"https://media.zenfs.com/en/globenewswire.com/cd1b6f0f04b27dd51e3e0af52fefc5f0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZXm0WIRUy_.i8bpwMH7VDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cd1b6f0f04b27dd51e3e0af52fefc5f0","width":300,"height":110}},"lazy":false},{"type":"text","content":"LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix” or the “Company”), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.001, which will become effective at 12:01 a.m. Eastern Time on Monday, September 15, 2025. The Company’s common stock will continue to trade under Biodesix’s existing trading symbol, BDSX, on the Nasdaq Global Market (“Nasdaq”) on a split-adjusted basis when the market opens on Monday, September 15, 2025, with the new CUSIP number 09075X207.","length":621,"tagName":"p"},{"type":"text","content":"The Reverse Stock Split was approved by Biodesix’s stockholders at the annual meeting held on May 20, 2025, with the final ratio subsequently determined by the Company’s board of directors. As a result of the Reverse Stock Split, every 20 shares of the Company’s pre-split common stock issued and outstanding will be automatically reclassified into one new share of the Company’s common stock. The Reverse Stock Split will reduce the number of shares of common stock issued and outstanding from approximately 156 million to approximately 8 million, subject to adjustment due to the payment of cash in lieu of fractional shares. There will be no change to the number of authorized shares or the par value per share.","length":714,"tagName":"p"},{"type":"text","content":"The Reverse Stock Split will affect all stockholders uniformly and will not alter any stockholder’s percentage ownership interest, except to the extent that the Reverse Stock Split results in fractional share amounts. Stockholders who would otherwise hold a fractional share of common stock will receive a cash payment in lieu of such fractional share.","length":352,"tagName":"p"},{"type":"text","conte...

More updates from Biodesix, Inc.

reverse stock splitThe CompanyBiodesixcommon stockstockholdersauthorized sharesfractional sharesNasdaqCompanyfractional share